June 20, 2018
FDA letter updates risks of Type III endoleaks with aortic endovascular graft systems
Editor's Note
In a June 19 letter to healthcare providers, the Food & Drug Administration (FDA) says it continues to evaluate information from several sources, including manufacturers, on the risks associated with Type III endoleaks with various endovascular graft systems used for treatment of abdominal aortic aneurysms (AAAs) and aorto-iliac aneurysms.
Based on new information, the FDA says the Endologix AFX with Strata device is at greater risk for Type III endoleaks than other endovascular AAA graft systems.
Free Daily News
- New planning tool aims to boost success of surgical quality improvement projects
- Charlotte surgical institute launches as US hub for robotic, minimally invasive training
- Senator pushes for national nurse-to-patient ratios, sounds alarm on patient safety
- Save the date: OR Manager Conference celebrates leadership, innovation, community
- Closing keynote: The Trick to Making Difficult Behaviors Disappear
- Session: Creating transparent paths to career growth to retain staff and boost morale
- Session: Advocacy in action—Empowering your teams toward successful legislative integration, safety excellence
- Session: Helping leaders uphold accountability, cultivate a positive culture to boost nurse retention
- Afternoon keynote: Reclaiming Balance, Joy, and Purpose in Your Career
- Session: Keep calm and recover—Essential service recovery tools for new OR leaders
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement